Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Clinical insights
Key research benefits
The only cathelicidin antimicrobial peptide made by the human body — active against bacteria, fungi, and some viruses.
- Broad-spectrum antimicrobial action via membrane disruption — a mechanism harder for pathogens to develop resistance against than conventional antibiotics.
- Accelerated wound healing vs. placebo in randomized controlled trials for both venous leg ulcers and diabetic foot ulcers.
- Penetrates bacterial biofilms (up to 100–1,000x more antibiotic-resistant than free bacteria) and shows lab-based synergy with antibiotics like vancomycin.
Research backing
Gronberg et al., 2014 (venous leg ulcer RCT, n=34) plus 2021 multicenter follow-up; 2023 diabetic foot ulcer RCT (n=25). Strongest human evidence is topical — no published human trials exist for injectable use.
Research Grade Formula
LL37
Immune & Specialized Support
LL37 · 5mg
$90
Express Shipping $20 — Australia only
- Third-party tested
- Non-GMO
- GMP certified
How to use
Follow research handling and reconstitution guidance for this compound. Always use appropriate lab technique and sterile materials.
Research Dosage ProtocolWhat's inside
Inside this vial is LL-37, a human cathelicidin-derived antimicrobial research peptide examined in host-defense and barrier-biology studies. Provided as a lyophilized powder for research reconstitution.
Technical overview
- Contents: LL-37 research peptide, 5 mg per vial
- Class: Cathelicidin antimicrobial peptide fragment
- Purity: ≥99% HPLC-confirmed
- Appearance: White lyophilized powder
- Solubility: Aqueous reconstitution recommended
- Documentation: Batch COA available on request
Reconstitute with bacteriostatic water at room temperature. For laboratory research and educational use only — not for human consumption.
Customer reviews
4.9
Based on 312 reviews